Open AccessCytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis
Author(s) -
Yusuf Yılmaz,
Alla Eldeen Kedrah,
Osman Özdoğan
Publication year - 2009
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.15.4387
Subject(s) - nonalcoholic fatty liver disease , cirrhosis , medicine , steatohepatitis , liver biopsy , context (archaeology) , fatty liver , chronic liver disease , metabolic syndrome , fibrosis , gastroenterology , biomarker , nonalcoholic steatohepatitis , liver disease , disease , pathology , biopsy , biology , obesity , paleontology , biochemistry
Nonalcoholic fatty liver disease (NAFLD) remains a leading cause of chronic liver disease. In the context of NAFLD, the presence of nonalcoholic steatohepatitis (NASH) portends an adverse prognosis with greater risk of liver fibrosis and cirrhosis. Although liver biopsy is the keystone of patient management in NAFLD, it is also increasingly clear that such evaluation has its limitations. The availability of biochemical markers of NAFLD and NASH has tremendous potential to radically alter management strategies for these conditions, as well as to monitor disease activity. Our article provides an overview of biomarker discovery and selection in the setting of NAFLD and highlights future directions in the field.